The pitch deck is ready. The science is solid. The clinical need is real. But here’s what many MedTech founders underestimate: before an investor ever schedules a call, they’ve already formed an impression — and that impression was shaped by your digital presence, your regulatory posture, and the story your data tells. Marketing in …
Every month your FDA submission is delayed is costing you more than time — it’s burning capital, weakening your market position, and increasing investor risk in ways most MedTech teams underestimate. You already know regulatory delay is bad. But most founding teams treat it like a weather event — unfortunate, outside your control, something to …
Most medical device companies entering the U.S. market take the 510(k) route. As of October 1, 2023, the only way to submit a 510(k) for most devices is through the FDA’s eSTAR template. As of October 1, 2025, the same is true for De Novo requests. The shift from open-format PDF submissions to a structured, validated electronic template is the most …
In MedTech, an unexplained answer is a dangerous one. Traditional AI often provides results without a rationale. This leaves clinical and regulatory teams to fill in the blanks. QualiVerse champions Explainable AI (XAI) to ensure every output is backed by a clear, human-readable logic.
AI coding tools are changing how MedTech teams build. But building faster and clearing faster are two very different things. Here is what founders need to understand before they confuse one for the other. If you are a MedTech founder who has spent any time with AI coding tools in the last year, you have probably had the same …
As a Physician-led Al-enabled SaMD, we relied on QMB for all our regulatory compliance needs. What differentiate them above the rest is QualiVerse. QualiVerse was able to expedite selecting our product code, predicate device, and design planning documents in a record time for pre-submission with the FDA. This also augmented our investment efforts.
